The trial results, presented at the 20th Annual WORLDSymposium™ by Dr. Paul Harmatz from UCSF Benioff Children’s Hospital, indicate that RGX-121 could significantly improve vital brain functions in patients with MPS II. Kenneth T. Mills, President and CEO of REGENXBIO, expressed optimism regarding the trial outcomes and the company’s expedited efforts to file a Biologics License Application (BLA) within the year, following constructive discussions with FDA leadership about the possibility of accelerated approval based on the trial’s comprehensive data.
A key highlight from the trial is the observed reduction in cerebrospinal fluid (CSF) levels of D2S6, a biomarker indicative of brain disease activity in MPS II patients. The pivotal phase reported an 86% median reduction in D2S6 levels, approaching normal ranges. These findings are consistent with earlier phases of the CAMPSIITE trial, where patients demonstrated significant neurodevelopmental improvements, surpassing natural history data expectations.
Furthermore, the trial presented a potential paradigm shift in MPS II treatment strategies, suggesting that patients receiving RGX-121 could either discontinue or avoid initiation of enzyme replacement therapy (ERT), which is currently a standard care practice. This development represents a significant step forward in managing MPS II, offering a one-time gene therapy solution that may reduce the treatment burden on patients and their families.
Regenxbio’s results from the RGX-121 trial contribute meaningful advancements in the treatment landscape for MPS II, showcasing the gene therapy’s potential to alter existing treatment protocols for this genetic disorder. The trial’s success in reducing critical biomarkers and the prospective reduction or elimination of the need for continuous enzyme replacement therapy position RGX-121 as a promising therapeutic option. Regenxbio is moving forward with regulatory processes, preparing to submit a Biologics License Application to the FDA, aiming to introduce this new treatment to patients with Hunter syndrome.
https://www.pmlive.com/pharma_news/regenxbios_investigational_gene_therapy_shows_promise_in_hunter_syndrome_1508145
https://www.prnewswire.com/news-releases/regenxbio-announces-pivotal-trial-of-rgx-121-for-the-treatment-of-mps-ii-achieves-primary-endpoint-302056283.html
Check out our AAV CDMO service to expedite your gene therapy research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Exploring Tau Protein’s Role in Glaucoma: New Insights and Therapeutic Potential
Glaucoma, a chronic neurodegenerative disorder, leads to irreversible vision loss by damaging retinal ganglion cells (RGCs) and the optic nerve, often associated with increased intraocular pressure (IOP). Despite the benefits of IOP-lowering treatments, the underlying...
FDA-mandated CAR-T monitoring period could be halved, say researchers
In patients with diffuse large B-cell non-Hodgkin lymphoma (DLBCL), the two hallmark post-chimeric antigen receptor (CAR)-T therapy toxicities are extremely rare after two weeks, supporting a shorter, more flexible toxicity monitoring period, according to a study...
Ancestral CRISPR-Cas13 Ribonucleases Discovered: Implications for Genome Editing
In a pioneering study published in *Science*, a team of researchers led by Peter H. Yoon and Jennifer A. Doudna from the University of California, Berkeley, has made a remarkable discovery in the realm of CRISPR technology. The team has identified an ancestral clade...
KBI Biopharma Expands Manufacturing Contract with Global Pharmaceutical Company
KBI Biopharma Inc., a JSR Life Sciences company and global cGMP contract development and manufacturing organization (CDMO), has extended and expanded its manufacturing contract with a leading global pharmaceutical company. Originally initiated in 2020, the renewed...
Related Services